# Metabolomic fingerprints of clustered preterm and term neonates – a pilot study

## TL;DR

This pilot study explores how different patterns of adrenal steroid metabolism in neonates correlate with health outcomes like BPD, IVH, and mortality.

## Contribution

The study introduces metabolomic clustering of adrenal steroids in neonates to identify associations with clinical outcomes.

## Key findings

- Three distinct steroid metabolomic clusters were identified, each linked to specific clinical risks.
- Suppressed steroidogenesis correlated with higher rates of BPD, SGA, and mortality.
- Excessive cortisol output was associated with increased IVH risk, while robust steroidogenesis supported better outcomes.

## Abstract

Adrenal steroidogenesis plays a pivotal role in neonatal adaptation, and advanced steroid profiling offers novel insights into disease risks and personalized management strategies. This study aimed to identify adrenal steroid metabolomic clusters in neonates and to correlate them with clinical outcomes.

In a prospective observational design (June 2021–July 2022), 50 neonates (12 early preterm, 18 late preterm, and 20 full-term) admitted with respiratory distress underwent continuous 24-hour urine collection via an urinary catheter. Steroid profiles were analyzed by gas chromatography–mass spectrometry. K-means clustering was employed to classify the metabolomic data, which were subsequently correlated with mortality, bronchopulmonary dysplasia (BPD), small for gestational age (SGA), and intraventricular hemorrhage (IVH).

K-means analysis delineated three distinct metabolic clusters. Cluster 1 displayed a profoundly suppressed steroidogenesis (low C19 and C21 excretion, diminished 3β-hydroxysteroid dehydrogenase and 5α-reductase activities), correlating with an increased incidence of BPD, high mortality risk scores, and significant rates of SGA/intrauterine growth restriction. Cluster 2 exhibited adrenal hyperactivation with elevated cortisol/cortisone derivatives, moderately increased C19/C21 metabolites, and partial 3β-HSD deficits, associated with a heightened risk of IVH and mortality. Cluster 3 showed robust steroidogenesis (high C19/C21 excretion and high 3β-HSD/5α-reductase activities), accompanied by the lowest mortality rates and absence of BPD or SGA/IUGR.

Suppressed steroidogenesis increased BPD, SGA, and mortality, while excessive cortisol output in Cluster 2 was associated with a higher risk of IVH. Robust steroidogenesis supported favorable outcomes, highlighting the potential for metabolome-guided interventions.